{"id":51008,"date":"2022-11-17T19:02:47","date_gmt":"2022-11-17T18:02:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/"},"modified":"2022-11-17T19:02:47","modified_gmt":"2022-11-17T18:02:47","slug":"international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/","title":{"rendered":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference"},"content":{"rendered":"
\n

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers<\/a>—C2<\/sub>N Diagnostics<\/a>, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD\u00ae blood test, p-tau MAA\u2122 and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer\u2019s disease at the Clinical Trials on Alzheimer’s Disease<\/a> (CTAD) conference.\n<\/p>\n

<\/a><\/p>\n

\nOf high interest will be multiple late-breaker oral presentations regarding C2<\/sub>N innovations, including CEO Dr. Joel B. Braunstein\u2019s on December 2. During the presentation he will share new data about the clinical diagnostic usefulness of the PrecivityAD\u00ae test and its impact on medical decision-making among practicing neurologists.\n<\/p>\n

\nOther C2<\/sub>N-related presentations at CTAD, occurring November 29 \u2013 December 2 in San Francisco, include the following:\n<\/p>\n

\nTuesday, November 29 (all times PST)<\/b>\n<\/p>\n

\n10:15 a.m.
\n
CTAD EU\/US Task Force on Blood Biomarkers
\n
Point of view from assay industry
\n
Dr. Joel B. Braunstein, C2<\/sub>N Diagnostics, St. Louis, MO (United States)\n<\/p>\n

\nWednesday, November 30<\/b>\n<\/p>\n

\n9:20 a.m.
\n
CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials\n<\/p>\n

\nOral Presentations
\n
1: Relationship between blood plasma and CSF measures of A\u03b2 42\/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer\u2019s disease
\n
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States)
\n
3: Implementation of plasma biomarkers into clinical practice and trials
\n
Oskar Hansson, Lund University, Lund (Sweden)\n<\/p>\n

\n10:30 a.m.
\n
Late Breaker #1 \u2013 Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials
\n
Keith Johnson, Massachusetts General Hospital, Boston, MA (United States)\n<\/p>\n

\n10:45 a.m.
\n
Late Breaker #2 \u2013 Plasma levels of Abeta42\/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD
\n
Robert Rissman, UC San Diego, La Jolla, CA (United States)\n<\/p>\n

\n3:15 p.m.
\n
Late Breaker #4 \u2013 CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer\u2019s disease.
\n
Kanta Horie, Washington University School of Medicine, St. Louis, MO (United States)\n<\/p>\n

\nFriday, December 2<\/b>\n<\/p>\n

\n9:20 a.m.
\n
Late Breaker #12 \u2013 Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients with Symptoms of Cognitive Impairment
\n
Dr. Joel B. Braunstein, C2<\/sub>N Diagnostics, St. Louis, MO (United States)\n<\/p>\n

\nCTAD Posters Featuring Data on the PrecivityAD\u00ae Test<\/b>\n<\/p>\n

\nTheme \u2013 Clinical Trials: Methodology
\n
Tuesday, November 29 at 4:00 p.m. to Wednesday, November 30 at 6:00 p.m.\n<\/p>\n

\nLP09 The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer’s Disease Trials
\n
Sarah Walter, Alzheimer\u2019s Therapeutic Research Institute, USC \u2013 San Diego, CA (United States)\n<\/p>\n

\nTheme \u2013 Clinical Trials: Biomarkers including plasma\n<\/p>\n

\nThursday, December 1 at 8:00 a.m.- 6:00 p.m.
\n
P109 Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer\u2019s Disease
\n
Charisse N. Winston, UC San Diego, La Jolla, CA (United States)\n<\/p>\n

\nP118 Recruitment of amyloid positive individuals and early Alzheimer\u2019s patients in a primary care setting \u2013 results from the BioFINDER Primary Care study
\n
Sebastian Palmqvist, Lund University, Malm\u00f6 (Sweden)\n<\/p>\n

\nP121 Use of the PrecivityAD\u00ae blood test in regular clinical practice: Preliminary observations from a dementia clinic
\n
Jonathan Drake, Rhode Island Hospital, Providence, RI (United States)\n<\/p>\n

\nAbout C2<\/sub>N Diagnostics, LLC<\/b>\n<\/p>\n

\nC<\/i>\u2082<\/i>N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation\u00ae. C<\/i>\u2082<\/i>N strives to provide exceptional laboratory services and products in the field of brain health. C<\/i>\u2082<\/i>N\u2019s biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit <\/i>www.C2N.com<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA:
\n
Adam Shapiro
\n
Adam.Shapiro@ASPR.bz<\/a>
202-427-3603\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD\u00ae blood test, p-tau MAA\u2122 and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer\u2019s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Of high interest will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51008","6":"format-standard","7":"category-industry"},"yoast_head":"\nInternational Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD\u00ae blood test, p-tau MAA\u2122 and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer\u2019s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Of high interest will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-17T18:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference\",\"datePublished\":\"2022-11-17T18:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/\"},\"wordCount\":649,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117005965\\\/en\\\/1641870\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/\",\"name\":\"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117005965\\\/en\\\/1641870\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-11-17T18:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117005965\\\/en\\\/1641870\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117005965\\\/en\\\/1641870\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/","og_locale":"en_US","og_type":"article","og_title":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend","og_description":"ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD\u00ae blood test, p-tau MAA\u2122 and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer\u2019s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Of high interest will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-17T18:02:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference","datePublished":"2022-11-17T18:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/"},"wordCount":649,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/","url":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/","name":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg","datePublished":"2022-11-17T18:02:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221117005965\/en\/1641870\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/international-researchers-poised-to-learn-new-insights-about-c2n-diagnostics-blood-test-innovations-at-clinical-trials-on-alzheimers-disease-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"International Researchers Poised to Learn New Insights About C2N Diagnostics\u2019 Blood Test Innovations at Clinical Trials on Alzheimer\u2019s Disease Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51008"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51008\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}